A Phase 2, Two Stage, Open-label, Clinical Trial to Determine the Therapeutic Effect and Safety of an Oral JAK2-inhibitor (INCB018424) in Patients With Relapsed or Refractory Multiple Myeloma
Overview
- Phase
- Phase 2
- Intervention
- Ruxolitinib 25 mg
- Conditions
- Multiple Myeloma
- Sponsor
- Incyte Corporation
- Enrollment
- 13
- Primary Endpoint
- Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
Detailed Description
The protocol was originally designed as a Simon two stage but after it was determined that the initial 13 patients enrolled did not meet the definition of a 'responder' according to the International Uniform Response Criteria for multiple myeloma the protocol was amended to allow patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion or had withdrawn consent to have 40 mg of dexamethasone added to their dose of ruxolitinib.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Confirmed diagnosis of multiple myeloma with evidence of measurable disease.
- •Relapsed or refractory disease with at least one line of prior therapy.
- •Adequate bone marrow reserve.
Exclusion Criteria
- •Received anti-cancer medications or investigational therapy in the past 28 days.
- •Intracranial disease or epidural disease.
Arms & Interventions
Ruxolitinib then Ruxolitinib + Dexamethasone
Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
Intervention: Ruxolitinib 25 mg
Ruxolitinib then Ruxolitinib + Dexamethasone
Patients received ruxolitinib 25 mg orally twice daily (bid) in each treatment cycle of 28 days. For those patients who had disease progression at any time or stable disease for 3 cycles and did not meet a withdrawal criterion, or withdrew consent, then 40 mg of dexamethasone was added to ruxolitinib on Days 1 to 4, 9 to 12, and 17 to 20 of four 28-day cycles. After the 4th cycle, 40 mg of dexamethasone was administered only on Days 1 to 4 of each subsequent cycle. Patients could continue to receive monotherapy or combination therapy indefinitely as long as no withdrawal criterion was met, did not have progressive disease and were receiving some clinical benefit.
Intervention: Dexamethasone 40 mg
Outcomes
Primary Outcomes
Number of Responders According to the International Uniform Response Criteria for Multiple Myeloma
Time Frame: Day 1 of Cycles 2, 3, and 4 and then every 3 months thereafter (up to 25 months).
A responder is defined as a patient with a complete response (negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow) or a partial response (≥ 50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥ 90% or to \< 200 mg per 24 h).
Secondary Outcomes
- Time to Disease Progression According to the International Uniform Response Criteria for Multiple Myeloma(Day 1 of Cycles 2, 3, and 4 and then every 3 months thereafter (up to 25 months).)